|
|
|
LifeScienceHistory.com - Check us out on Instagram
Texas Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing TexasLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Pelican Therapeutics
| | | Phone: | (917) 892-9996 | Year Established: | 2009 | Ticker: | HTBX | Exchange: | NASDAQ | Main Contact: | Rahul R Jasuja, Ph.D., CEO | | Company Description | Pelican Therapeutics, a subsidiary of Heat Biologics, is an immuno-oncology company focused on developing agonists to TNFRSF25, a differentiated and potentially best-in-class T cell costimulatory receptor. TNFRSF25 has shown great promise due to its preferential specificity for stimulating the production of "memory" CD8+ T cells, the strongest predictive biomarker of clinical benefit from cancer immunotherapy. T cell costimulatory therapy, when combined with checkpoint inhibitors and other treatments, could significantly improve clinical responses for a broader range of patients. Pelican has conducted extensive preclinical studies and completed humanization of its lead monoclonal antibody, PTX-25.
On May 1, 2017, Heat Biologics announced the company has completed the acquisition of an 80% controlling interest in Pelican Therapeutics. | |
|
|
|
|
|